Federal law now requires a marketing authorisation holder to appoint more than one importer, and in February 2026 the regulator activated a mechanism to end single-agent control of a product. Yet the authorisation still sits in your distributor’s name. We build the candidate list for that structure, check what each firm is actually licensed to do, and rank them by what they may lawfully carry.
Three systems sit on top of each other here and brand owners routinely plan for only one. Medicines and devices are authorised federally, by the Emirates Drug Establishment, since it took that role from the health ministry in 2023. Facilities, professionals and promotional activity are regulated by the emirate: Dubai through its health authority, Abu Dhabi through its department of health, which also runs its own drug coding and a special-authorisation route for products it has not coded. And free zones form a third layer with their own licensing, Dubai Healthcare City requiring both its own authority’s permits and the emirate health authority’s licences.
Pricing is federal and binding. Maximum prices are set, discounting below them is generally not permitted, and the penalty runs to a hundred thousand dirhams per violation and doubles for a repeat. Innovator prices are expected to fall into line once a generic arrives, and biosimilars are held to a proportion of the reference product’s landed cost. Build the commercial case on the price you will be allowed rather than the one your global team assumed.
Start with who regulates this. Medicines and medical devices moved to the Emirates Drug Establishment in 2023, so a candidate or an adviser still describing a health-ministry registration is working from a system that has been replaced. Licensing under it is narrower than most brand owners expect: a medical store may hold title to product, import it, sell it and re-export it, while a medical warehouse may only store, and import, export, re-export and distribution are licensed as separate activities. Behind the licence sits a good storage and distribution certificate that is granted only after an inspection passes.
Then the part that inverts the usual negotiation. Since the 2024 medical products law, a marketing authorisation holder must appoint at least two importers, and from February 2026 the regulator has required more than one authorised agent per product, expressly to break single-agent control. At the same time a registered commercial agency still carries territorial rights, and the authorisation itself is held locally, so a product already registered cannot simply move to a new firm while the incumbent is in place. Those two pull against each other and the regulator had not published how they reconcile as of October 2026. Which makes it something to settle in your agreement rather than in a later argument.
The healthcare and pharmaceutical cluster at Jebel Ali runs to several hundred companies from dozens of countries, and only about a tenth of them manufacture. The rest trade, store and move goods onward. That tells you what most of the sector here actually is: a logistics and redistribution business attached to a port, serving the Gulf, the subcontinent and Africa as much as the domestic market.
It is also a channel where ownership runs in directions a brand owner does not always check. One of the region’s larger pharmaceutical manufacturers acquired full control of a distribution and retail pharmacy group operating hundreds of stores and multiple distribution hubs across three countries. So the firm proposing to carry your product may be owned by a company that competes with it, and may own the pharmacy shelf you are trying to reach. Map the group before you discuss terms, not after.
Territory needs the same discipline. Candidates here commonly operate across the Gulf, re-export is a licensed activity in its own right, and a grant of “the UAE” to a company whose economics are built on onward shipment will quietly fund its regional business with your brand — in markets you may be about to appoint someone else in.
The single most common error we see in this market is treating a licence as a licence. Here the permissions are granular, and a company can be entirely legitimate and still unable to do the specific thing you need.
The UAE rewards documentary diligence because the documents exist and are specific. These are the ones worth seeing.
Ask to see each licence rather than a company profile. A firm licensed to distribute but not to import, or to store but not to take title, cannot run your supply chain however impressive the warehouse is.
It is granted only after an on-site inspection passes, and it is a condition of the warehouse licence. Check the date, and ask what the inspection found.
Since the law requires at least two importers and the regulator now requires more than one authorised agent per product, this is not hypothetical. A candidate with no view on it has not read the regime they operate in.
Abu Dhabi government, the Abu Dhabi hospital operator and the federal health service each run a separate registration with different requirements. Holding one is not holding the others.
Free zone firms sit outside mainland jurisdiction and are excluded from federal tendering unless they hold a branch outside the zone, with medicine suppliers exempted. Establish which entity is actually contracting.
Vertical integration into manufacturing and retail pharmacy is common here. The question is not whether a candidate carries competing lines but whether its parent makes them.
It is held on the UAE side and a product already registered cannot simply move to a new firm while the incumbent is in place. Agree who applies, who holds it and what happens to stock, in the first agreement.
A candidate whose pitch is that appointing them locks the category is selling something the rules are actively taking apart. The real design problem is how two or more appointed firms are kept from competing each other down.
Re-export is a licensed activity and much of the cluster exists to do it. Silence on territory is not neutrality; it is a grant.
Import, export, re-export and distribution are separate, and a medical store is not a medical warehouse. Deals get signed on the assumption that a licensed company can do all of it.
Maximum prices are set federally and discounting below them is generally not allowed. A plan built on a target price rather than the permitted one will not survive contact with the first submission.
The Emirates Drug Establishment, federally, since it took over from the Ministry of Health and Prevention in 2023; the ministry’s own portal now directs applicants to it. Emirate authorities still regulate facilities, professionals and promotion, and Abu Dhabi additionally runs its own drug coding with a special-authorisation route.
Not in the way most brand owners mean. The 2024 medical products law requires a marketing authorisation holder to appoint at least two importers, and from February 2026 the regulator has required more than one authorised agent per product, expressly to end single-agent control. A registered commercial agency still carries territorial rights, and the regulator had not published how the two reconcile as of October 2026.
A medical store may hold title to product, import it, sell it and re-export it. A medical warehouse may only store. The distinction decides whether a candidate can actually run your business, and it is visible on the licence.
It can hold stock and re-export, but free zone entities sit outside mainland jurisdiction and generally cannot sell directly into it, so a mainland distributor or a mainland presence is needed. For federal health tendering, free zone vendors are excluded unless they hold a branch outside the zone, with an exemption for medicine suppliers.
It is held on the UAE side, not by the overseas manufacturer, and the registration reflects that. A product already registered cannot simply be moved to a new firm while the incumbent remains in place, so the exit mechanics belong in the agreement from the start.
No. Maximum prices are set federally and discounting below the set price is generally not permitted, with penalties up to a hundred thousand dirhams per violation and double for repeats. Innovator pricing is expected to adjust once a generic enters, and biosimilars are held to a proportion of the reference product’s landed cost.
The structural decisions here cannot easily be unwound: how many importers you appoint, which licensed activities each one actually holds, and who the authorisation sits with. Tell us what you are placing and we will come back with the structure we would recommend and why.
How we verify How a distributor search runs